Production (Stage)
Telomir Pharmaceuticals, Inc.
TELO
$2.07
-$0.03-1.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.46M | -16.53M | -22.96M | -18.74M | -18.84M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 0.00 | 4.34M | 5.08M | 5.83M | 5.95M |
| Total Other Non-Cash Items | 8.37M | 7.00M | 12.28M | 7.49M | 7.49M |
| Change in Net Operating Assets | 90.80K | 126.40K | 48.90K | -1.12M | 343.30K |
| Cash from Operations | -3.99M | -5.07M | -5.55M | -6.55M | -5.06M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 0.00 | 0.00 | 1.07M | 2.76M | 3.12M |
| Total Debt Repaid | -433.90K | -534.90K | -404.90K | -101.00K | -101.00K |
| Issuance of Common Stock | 1.04M | 6.87M | 5.92M | 5.92M | 5.92M |
| Repurchase of Common Stock | -- | -- | -- | -- | -90.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 519.50K | 0.00 | -200.40K | -160.10K | -511.60K |
| Cash from Financing | 1.12M | 6.34M | 6.38M | 8.42M | 8.34M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.87M | 1.26M | 832.20K | 1.87M | 3.27M |